Kimiteru Ito, MD, PhD

The tumor-to-normal ratio of maximum uptake (Tmax/N) on 18F-BPA PET is widely used to guide decision-making regarding boron neutron capture therapy (BNCT). However, intratumoral heterogeneity of boron drug distribution may also influence clinical outcomes. Th...

In BNCT, 18F-BPA-PET evaluates boron drug distribution for treatment eligibility, but is rarely incorporated into treatment planning. A key limitation is differences in drug administration protocols between PET and BNCT, which may weaken clinical outcome-to-d...